Star Combo Pharma Ltd (S66) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Star Combo Pharma Ltd stock A$0.10, price A$0.14, that is 28.6% below the price, quality 44 out of 100. Rating: overvalued. Calculated from audited financials with 23 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.
How to read this chart
60‑month range A$0.0846 – A$0.3339 · fair‑value band A$0.0700 – A$0.1400 · the A$0.1400 price screens above the A$0.1000 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.
Follow Star Combo Pharma in your weekly email
Every Wednesday you see whether Star Combo Pharma is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Star Combo Pharma Limited manufactures and distributes health food products and nutritional supplements in Australia and China. It operates in two segments, OEM and Retail. The company develops, manufactures, markets, and sells natural health supplements and skin care products.
Show moreShow less
It also provides its products through e-commerce platform to Chinese health product consumers. The company sells its products under the Costar, Living Healthy, Amax, and J&K brands. Star Combo Pharma Limited was founded in 2004 and is based in Smithfield, Australia.
Stock analysis
Star Combo Pharma Ltd (S66) currently trades at A$0.1400, while our model-based Fair Value estimate is A$0.1000, 29% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Economic Profit group reads highest at a median of A$0.1900 per share, and 6 of the 23 models we run sit above the A$0.1400 price.
Bear case: the Earnings-Based group reads lowest at A$0.0200, and 17 of the 23 models stay below the price. Data coverage for this calculation is low.
Scenario range: A$0.0700 (bear) to A$0.1400 (bull), the price of A$0.1400 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 44/100 (below-average quality), in the Consumer Defensive sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Star Combo Pharma Ltd reported revenue of A$23.6M in FY2026 versus A$22.9M in FY2022, a compound +0.7%/yr. Reported net income was A$395K in FY2026.
Key figures
Market cap A$18.9M (≈ $13.0M) Micro · P/S ratio 0.80 · Dividend yield 2.1% · Net margin 1.7% · Return on equity 1.0% · Return on assets (EBIT) 0.4% (5-year average) · Operating margin −1.3% · Revenue (TTM) A$23.6M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 27 out of 100 (low confidence).
What moves the price
The share trades about 47% below its 52-week high and 30% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at −26% fair-value upside, at −29%, S66 screens richer than that median.
Fair Value models
BearA$0.0700Fair Value A$0.1000BullA$0.1400
Price A$0.1400 · Downside -28.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−15.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.5%
Start year 2021 (pandemic). Over 10 years: +9.7% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.7%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 3 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−17.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year−19.2%
Dividend (yield on the price)2.1%
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−8% → −1%
Growth Forecast
Little optimism in the price
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
less than -40 %
The company could shrink this much every year for the next five years and today's price would still be justified.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Household & Personal Products · 230 stocks
Beats the industry median on 2/12 measures
Overall it trails its industry peers.
Valuation
Quality Score44 · Bottom 25%
Fair Value upside−28.6% · Below median
Profitability
Return on equity (12 months)1.0% · Below median
Return on assets0.8% · Below median
Net margin (12 months)1.7% · Below median
Operating margin (12 months)−1.3% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)−3.5% · Bottom 25%
Dividend yield (12 months)2.1% · Below median
Valuation Multiplesvs Household & Personal Products median · lower = cheaper
P/B0.49× · Cheapest 25%
P/S (12 months)0.80× · Cheaper than median
Price / free cash flow (fiscal year)23.0× · Pricier than median
EV/EBITDA12.3× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 36
FUTURE (revenue growth)0· sector 20
PAST (return on equity)4· sector 31
HEALTH (low debt)100· sector 98
DIVIDEND (yield)43· sector 53
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Star Combo Pharma Ltd (S66) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of A$0.1000 versus a price of A$0.1400, about 29% lower (overvalued).
What is the fair value of S66?
Our model-based fair value for Star Combo Pharma Ltd is A$0.1000 (as of Nov 4, 2026), built from audited fundamentals. The current price: A$0.1400.
What is the quality score of S66?
Star Combo Pharma Ltd has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Star Combo Pharma Ltd (S66)?
Our model-based price target is the fair value of A$0.1000 (as of Nov 4, 2026) from 23 valuation models. Cautious scenario A$0.0700, optimistic scenario A$0.1400. It is a calculation from audited fundamentals, not an analyst target.
What is the Star Combo Pharma Ltd stock forecast for 2026?
Our models put fair value at A$0.1000, about 29% lower versus a price of A$0.1400 (overvalued). Cautious scenario A$0.0700, optimistic scenario A$0.1400. The calculation is refreshed regularly with new filings.
What is the revenue of Star Combo Pharma Ltd (S66)?
Star Combo Pharma Ltd reported trailing-twelve-month revenue of about A$23.6M (latest available figure, as of Nov 4, 2026).
Does Star Combo Pharma Ltd pay a dividend?
Star Combo Pharma Ltd currently shows a dividend yield of 2.14% relative to its recent price (as of Nov 4, 2026).
How much is the dividend of Star Combo Pharma Ltd (S66) and when is the ex-dividend date?
Star Combo Pharma Ltd pays a dividend of A$0.003 per share a year, a dividend yield of 2.1%. The last ex-dividend date was Oct 13, 2026. The payout ratio is 103% of earnings. Free cash flow covers the dividend 2.03 times. Our assessment: Sustainable. Payout and cash coverage both look sustainable.
What growth is priced into Star Combo Pharma Ltd (S66)?
For today's price to be fair in a discounted-cash-flow model, Star Combo Pharma Ltd would have to grow free cash flow by less than minus 40 % per year for five years (discount rate 8.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -2.5 % per year. As of Nov 4, 2026.
What discount rate (WACC) does the fair value of S66 use?
Our models discount Star Combo Pharma Ltd at 8.3 %: a base by market capitalisation (nano), damped by beta 0.35, country premium for Australia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Star Combo Pharma Ltd that is less than minus 40 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (8.3 %) and the same formula as our fair value.
How much growth has Star Combo Pharma Ltd (S66) delivered so far?
Over the past 5 years revenue at Star Combo Pharma Ltd grew -2.5 % a year. The price currently implies free-cash-flow growth of less than minus 40 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Star Combo Pharma Ltd (S66) growing?
The median revenue growth in the sector is +3.6 % a year. That is the yardstick for the growth priced into Star Combo Pharma Ltd (less than minus 40 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Star Combo Pharma Ltd (S66)?
The free-cash-flow yield on the price is 4.35 %: that much free cash flow Star Combo Pharma Ltd produces per unit of market value. When it exceeds the discount rate of our models (8.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Star Combo Pharma Ltd (S66)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Star Combo Pharma Ltd it is A$0.1000 per share (as of Nov 4, 2026), against a price of A$0.1400. It is the blended result of 23 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Star Combo Pharma Ltd stock overvalued or undervalued in 2026?
As of Nov 4, 2026, S66 trades above its calculated fair value: price A$0.1400, fair value A$0.1000, a gap of about −29% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of S66?
No. The price is what the market pays today (A$0.1400); the fair value is what the company's own numbers justify (A$0.1000). For Star Combo Pharma Ltd the two are A$0.0400 per share apart. That gap is exactly why we show both numbers side by side.
How much is Star Combo Pharma Ltd worth?
The market values Star Combo Pharma Ltd at about A$18.9M (market capitalisation, as of Nov 4, 2026). Per share that is A$0.1400; our models calculate a fair value of A$0.1000 per share.
What do the bullish and bearish scenarios say about S66?
Our models span a range for Star Combo Pharma Ltd: cautious scenario A$0.0700, base A$0.1000, optimistic A$0.1400 per share (as of Nov 4, 2026, price A$0.1400). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Star Combo Pharma Ltd (S66)?
Balance-sheet figures for Star Combo Pharma Ltd (as of Nov 4, 2026): return on equity 1.0%. They feed the Quality Score of 44/100, which measures business quality independently of the share price.
How far is S66 from its 52-week high?
Star Combo Pharma Ltd trades at A$0.1400, about 47% below its 52-week high of A$0.2643 and 30% above the low of A$0.1077 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of A$0.1000 is for.
Which stocks are comparable to Star Combo Pharma Ltd?
From the same area (Consumer Defensive) we also value Colgate-Palmolive Company, Hindustan Unilever Limited, The Estée Lauder Companies Inc, Henkel AG, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Star Combo Pharma Ltd stock attractive at the current price?
The data as of Nov 4, 2026: price A$0.1400, calculated fair value A$0.1000 (−29%), Quality Score 44/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of S66 calculated?
We run Star Combo Pharma Ltd through 23 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of A$0.1000 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Star Combo Pharma Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Star Combo Pharma Ltd (S66)?
The closing price on Nov 6, 2026 was A$0.1400. Our model-based fair value is A$0.1000, about 29% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Star Combo Pharma Ltd right now?
Weak quality (44/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range (A$0.0700 to A$0.1400) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Star Combo Pharma Ltd
How large is the market capitalisation of Star Combo Pharma Ltd (S66)?
The market capitalisation of Star Combo Pharma Ltd is A$18.9M (≈ $13.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Star Combo Pharma Ltd (S66)?
The price-to-sales ratio of Star Combo Pharma Ltd is 0.80 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Star Combo Pharma Ltd (S66)?
The dividend yield of Star Combo Pharma Ltd is 2.1%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Star Combo Pharma Ltd (S66)?
The net margin of Star Combo Pharma Ltd is 1.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Star Combo Pharma Ltd (S66)?
The return on equity (ROE) of Star Combo Pharma Ltd is 1.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Star Combo Pharma Ltd (S66)?
On an EBIT basis the return on assets of Star Combo Pharma Ltd is 0.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Star Combo Pharma Ltd (S66)?
The operating margin of Star Combo Pharma Ltd is −1.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Star Combo Pharma Ltd (S66)?
Revenue at Star Combo Pharma Ltd is growing −3.5% versus a year earlier (3y avg −1.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does Star Combo Pharma Ltd (S66) carry?
The net debt of Star Combo Pharma Ltd is A$284K (fiscal year 2026, ≈ 0.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Star Combo Pharma Ltd in the live analysis
One click puts Star Combo Pharma Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 4, 2026